A patient with treatment-resistant schizophrenia and cytochrome P4502D6 gene duplication

Clinical Genetics

Volumn 61, Issue 2, 2002, Pages 152-154

  Kawanishi, Chiaki ^a   Furuno, T ^a   Kishida, I ^a   Matsumura, T ^a   Kosaka, K ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

CYP2D6; Gene duplication; Pharmacogenetics; Schizophrenia; Treatment resistance; Ultra rapid metabolizer

Indexed keywords

ANTIDEPRESSANT AGENT; CHLORPROMAZINE; CLOZAPINE; CYTOCHROME P450 2D6; HALOPERIDOL; LEVOMEPROMAZINE; NEUROLEPTIC AGENT; PERPHENAZINE; PSYCHOTROPIC AGENT; RISPERIDONE; THIORIDAZINE;

AGED; ARTICLE; CASE REPORT; DISEASE SEVERITY; DRUG MEGADOSE; DRUG METABOLISM; DRUG RESPONSE; ENZYME ACTIVITY; FEMALE; GENE DUPLICATION; GENE MUTATION; HUMAN; MOLECULAR GENETICS; PRIORITY JOURNAL; SCHIZOPHRENIA;

AGED; CYTOCHROME P-450 CYP2D6; DRUG RESISTANCE; FEMALE; GENE DUPLICATION; HUMANS; SCHIZOPHRENIA;

POMACANTHUS MACULOSUS;

EID: 0036488082     PISSN: 00099163     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-0004.2002.610211.x     Document Type: Article

References (10)

1. Juarez-Reyes MG, Shumway M, Battle C, Bacchetti P, Hansen MS, Hargreaves WN. Effects of stringent criteria on eligibility for clozapine among public mental health clients. Psychiatr Serv 1995: 46: 801-806.
2. Kane JM. Pharmacologic treatment of schizophrenia. Biol Psychiatry 1999: 46: 1396-1408.
3. Bertilsson L, Kalow W. Interethnic differences in drug disposition and effects. In: Pacifici, GM, Pelkonen, O, eds. Interindividual Variability in Drug Metabolism in Humans. London: Taylor & Francis, 2001, 15-74.
4. Bertilsson L, Dahl ML, Sjöqvist F, Åberg-Wistedt A, Humble M, Johansson I et al. Molecular basis for rational megaprescribing in ultrarapid hydroxylation of debrisoquine. Lancet 1993: 341: 63.
5. Baumann P, Broly F, Kosel M, Eap CB. Ultrarapid metabolism of clomipramine in a therapy-resistant depressive patient, as confirmed by CYP2D6 genotyping. Pharmacopsychiatry 1998: 31: 72.
6. American Psychiatric Association. Diagnostic and Statistical Manual for Mental Disorders, 4th edn. Washington: D.C. American Psychiatric Press 1994.
7. Lundqvist E, Johansson I, Ingelman-Sundberg M. Genetic mechanisms for duplication and multiduplication of the human CYP2136 gene and methods for detection of duplicated CYP2D6 genes. Gene 1999: 226: 327-338.
8. Marez D, Legrand M, Sabbagh N, Lo Guidice J-M, Spire C, Lafitte J-J et al. Polymorphism of the cytochrome P450 CYP2D6 gene in a European population characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenet 1997: 7: 193-202.
9. Nishida Y, Fukuda T, Yamamoto I, Azuma J. CYP2D6 genotypes in a Japanese population low frequencies of CYP2D6 gene duplication but high frequency of CYP2D6*10. Pharmacogenet 2000: 10: 567-570.
10. Aitchison KJ, Munro J, Wright P, Smith S, Makoff AJ, Sachse PC et al. Failure to respond to treatment with typical antipsychotics is not associated with CYP2D6 ultrarapid hydroxylation. Br J Clin Pharmacol 1999: 48: 388-394.